PriceTargets.com logo

NASDAQ:KOD - Kodiak Sciences Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $132.82
  • Forecasted Upside: 40.85 %
  • Number of Analysts: 11
  • Breakdown:
  • 1 Sell Ratings
  • 5 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$94.30 As of 11/26/2021 01:00 AM ET
▼ -5.58 (-5.59%)

This chart shows the closing price for KOD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Kodiak Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KOD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KOD

Analyst Price Target is $132.82
▲ +40.85% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Kodiak Sciences in the last 3 months. The average price target is $132.82, with a high forecast of $170.00 and a low forecast of $86.00. The average price target represents a 40.85% upside from the last price of $94.30.

This chart shows the closing price for KOD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 11 investment analysts is to hold stock in Kodiak Sciences. This rating has held steady since February 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
6/6/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
9/4/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
12/3/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
3/3/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
6/1/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
8/30/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
10/29/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
11/28/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/12/2021BMO Capital MarketsBoost Price TargetMarket Perform$104.00 ➝ $114.00Medium
11/11/2021CitigroupBoost Price TargetNeutral$103.00 ➝ $114.00Low
5/11/2021Roth CapitalUpgradeNeutral ➝ Buy$155.00 ➝ $149.00High
5/11/2021BMO Capital MarketsLower Price TargetMarket Perform$138.00 ➝ $104.00High
5/11/2021BarclaysLower Price TargetUnderweight$90.00 ➝ $86.00High
5/4/2021TruistBoost Price Target$89.00 ➝ $147.00Medium
5/4/2021Truist SecuritiesBoost Price TargetBuy$89.00 ➝ $147.00High
4/19/2021Morgan StanleyLower Price TargetEqual Weight$133.00 ➝ $119.00Low
3/11/2021Evercore ISIInitiated CoverageOutperformHigh
3/8/2021Morgan StanleyBoost Price TargetEqual Weight$125.00 ➝ $133.00High
3/8/2021BarclaysReiterated RatingEqual Weight ➝ Underweight$52.00 ➝ $90.00Medium
3/2/2021BMO Capital MarketsLower Price TargetMarket Perform$148.00 ➝ $138.00Medium
3/1/2021BarclaysDowngradeEqual Weight ➝ Underweight$52.00 ➝ $90.00Low
2/17/2021Roth CapitalDowngradeBuy ➝ Neutral$133.00 ➝ $155.00Low
1/25/2021BMO Capital MarketsDowngradeOutperform ➝ Market Perform$145.00 ➝ $148.00High
12/17/2020Berenberg BankInitiated CoverageBuy$156.00Medium
12/15/2020UBS GroupInitiated CoverageBuy$170.00Medium
12/11/2020Smith Barney CitigroupInitiated CoverageNeutral$134.00High
11/30/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$74.00 ➝ $125.00High
11/16/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$80.00 ➝ $125.00Low
11/13/2020BMO Capital MarketsBoost Price TargetOutperform$74.00 ➝ $145.00High
11/13/2020The Goldman Sachs GroupDowngradeNeutral$105.00Medium
11/10/2020Roth CapitalBoost Price TargetBuy$124.00 ➝ $133.00High
11/9/2020Roth CapitalBoost Price TargetBuy$115.00 ➝ $133.00High
7/28/2020SunTrust BanksLower Price TargetBuy$90.00 ➝ $89.00Low
5/14/2020SunTrust BanksLower Price TargetBuy$101.00 ➝ $90.00High
4/15/2020Morgan StanleyLower Price TargetOverweight$82.00 ➝ $80.00Low
3/31/2020BMO Capital MarketsInitiated CoverageOutperform$74.00High
3/2/2020The Goldman Sachs GroupInitiated CoverageBuy$80.00Medium
2/18/2020BarclaysDowngradeOverweight ➝ Equal Weight$69.00Medium
2/5/2020SunTrust BanksInitiated CoverageBuy$101.00High
1/23/2020Chardan CapitalReiterated RatingBuyHigh
1/8/2020Roth CapitalInitiated CoverageBuy$115.00Medium
1/3/2020HC WainwrightInitiated CoverageBuy$100.00Low
1/3/2020Jefferies Financial GroupInitiated CoverageBuy$100.00Low
12/24/2019JPMorgan Chase & Co.Initiated CoverageOverweight$82.00High
12/17/2019Morgan StanleyBoost Price TargetOverweight$33.00 ➝ $82.00High
12/2/2019Chardan CapitalReiterated RatingBuy$40.00High
11/13/2019Chardan CapitalReiterated RatingBuy$40.00High
10/15/2019Chardan CapitalBoost Price TargetBuy$22.50 ➝ $35.00High
6/13/2019Chardan CapitalReiterated RatingBuy$22.50Low
2/20/2019Chardan CapitalInitiated CoverageBuy ➝ Buy$22.50Medium
10/29/2018BarclaysInitiated CoverageOverweight ➝ Overweight$20.00High
10/29/2018Morgan StanleyInitiated CoverageOverweight ➝ Overweight$20.00High
10/29/2018Bank of AmericaInitiated CoverageBuy ➝ Buy$14.00High
(Data available from 11/28/2016 forward)

News Sentiment Rating

0.24 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/2/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/1/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/1/2021
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/31/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/30/2021
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2021
  • 2 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2021
  • 2 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
11/28/2021

Current Sentiment

  • 2 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Kodiak Sciences logo
Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline includes KSI-301 for wet AMD; KSI-301 for diabetic eye disease; KSI-501 for DME and uveitis; KSI-201 for resistant wet AMD; and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.
Read More

Today's Range

Now: $94.30
Low: $90.27
High: $100.17

50 Day Range

MA: $107.62
Low: $94.30
High: $128.49

52 Week Range

Now: $94.30
Low: $73.19
High: $171.21

Volume

195,046 shs

Average Volume

282,666 shs

Market Capitalization

$4.88 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.39

Frequently Asked Questions

What sell-side analysts currently cover shares of Kodiak Sciences?

The following Wall Street research analysts have issued research reports on Kodiak Sciences in the last twelve months: Barclays PLC, Berenberg Bank, BMO Capital Markets, Citigroup Inc., Evercore ISI, JPMorgan Chase & Co., Morgan Stanley, Roth Capital, Smith Barney Citigroup, Truist, Truist Securities, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for KOD.

What is the current price target for Kodiak Sciences?

11 Wall Street analysts have set twelve-month price targets for Kodiak Sciences in the last year. Their average twelve-month price target is $132.82, suggesting a possible upside of 40.8%. UBS Group AG has the highest price target set, predicting KOD will reach $170.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $86.00 for Kodiak Sciences in the next year.
View the latest price targets for KOD.

What is the current consensus analyst rating for Kodiak Sciences?

Kodiak Sciences currently has 1 sell rating, 5 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in KOD, but not buy more shares or sell existing shares.
View the latest ratings for KOD.

What other companies compete with Kodiak Sciences?

Other companies that are similar to Kodiak Sciences include Bio-Techne, Novozymes A/S, Novavax, Repligen, argenx, QIAGEN, Acceleron Pharma, Neurocrine Biosciences, CRISPR Therapeutics, Denali Therapeutics, Exelixis, Beam Therapeutics, Abcam, Fate Therapeutics and Halozyme Therapeutics.

How do I contact Kodiak Sciences' investor relations team?

Kodiak Sciences' physical mailing address is 2631 HANOVER STREET, PALO ALTO CA, 94304. The company's listed phone number is (650) 281-0850 and its investor relations email address is [email protected] The official website for Kodiak Sciences is kodiak.com.